Sepsis Market Report 2026

The sepsis market size has grown strongly in recent years. It will grow from $1.02 billion in 2025 to $1.11 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to high sepsis incidence, improved hospital care standards, adoption of clinical protocols, development of sepsis awareness programs, advanced ICU setups.

The sepsis market size is expected to see strong growth in the next few years. It will grow to $1.55 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to AI-assisted early detection, expansion of point-of-care monitoring, integration with EHR systems, advanced therapeutics for sepsis, global sepsis management guidelines adoption. Major trends in the forecast period include early sepsis detection tools, AI-powered risk scoring, point-of-care sepsis monitors, tele-icu integration, protocol-driven treatment solutions.

The rising burden of infectious diseases is expected to drive the growth of the sepsis market in the coming years. Infectious diseases are caused by bacteria, viruses, fungi, or parasites invading the body. Common examples include tuberculosis, influenza, ringworm, and malaria, which can spread through direct contact, contaminated sources, or insect vectors. The increasing incidence of infectious diseases is driven by population growth, globalization, environmental changes, drug-resistant pathogens, and gaps in healthcare systems. Sepsis is a severe complication that occurs when the body mounts an extreme response to infection, resulting in widespread inflammation and potential organ failure. For example, in November 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported 9,633 cases of tuberculosis (TB) in the United States in 2023, representing a 15.6% increase from 8,332 cases in 2022. Thus, the growing burden of infectious diseases is fueling the expansion of the sepsis market.

Key companies in the sepsis market are focusing on technologically advanced platforms, such as artificial intelligence (AI)-powered systems, to improve early diagnosis, enhance treatment precision, and predict patient outcomes, ultimately aiming to reduce mortality and improve healthcare efficiency in sepsis management. For instance, in June 2024, Predicate Healthcare Performance Group (HPG), a US-based healthcare company, launched OpenDX, an AI-enabled platform that integrates diagnostics with wearable biosensors to detect early signs of sepsis. This technology aids in sepsis diagnosis and has the potential to expand to other health conditions, demonstrating the role of AI in advanced diagnostics. Predicate’s chest sensor helps healthcare providers identify early signs of sepsis, a condition that is often challenging and frequently missed.

In April 2024, Prenosis Inc., a US-based biotechnology research company, partnered with Roche Holding AG. Through this collaboration, Roche will distribute Prenosis’ Sepsis ImmunoScore, an AI-driven software-as-a-medical-device designed to assist healthcare providers in rapidly diagnosing sepsis and predicting adverse outcomes, thereby improving clinical management of the condition. Roche Holding AG, based in Switzerland, develops medications for oncology, immunology, infectious diseases, and other therapeutic areas.

Major companies operating in the sepsis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck KGaA, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Asahi Kasei Corporation, Becton Dickinson and Company, bioMérieux SA, QuidelOrtho Corporation, DiaSorin S.p.A., Seegene Inc., EKF Diagnostics, Boditech Med Inc., Cytovale Inc., Alifax S.r.l., Hansa Biopharma, Amomed Pharma GmbH, Inotrem S.A., Abionic SA, Biosystems Inc., Immunexpress Inc.

North America was the largest region in the sepsis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sepsis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sepsis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the sepsis market by increasing costs for imported antibiotics, antifungal agents, diagnostic reagents, and intensive care equipment used to treat severe sepsis and septic shock. Hospitals and pathology laboratories in regions such as Asia-Pacific and Europe that rely heavily on global pharmaceutical and medical device suppliers have been most affected, leading to higher treatment costs and budget pressures. These challenges can slow the adoption of advanced therapeutic options in some healthcare systems. At the same time, tariffs are driving investment in domestic drug manufacturing and diagnostic production, which is strengthening supply reliability and improving long-term sustainability in the sepsis market.

The sepsis market research report is one of a series of new reports that provides sepsis market statistics, including sepsis industry global market size, regional shares, competitors with a sepsis market share, detailed sepsis market segments, market trends and opportunities, and any further data you may need to thrive in the sepsis industry. This sepsis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sepsis is a life-threatening condition resulting from the body's extreme reaction to an infection. It occurs when the immune system releases chemicals into the bloodstream to combat the infection, but these chemicals cause widespread inflammation, leading to tissue damage, organ failure, and potentially death.

The main categories in sepsis management are diagnosis and therapeutics. Diagnosis involves identifying sepsis in patients through various tests and procedures designed to detect infections and evaluate their severity. The pathogens responsible include bacteria, viruses, and fungi. Applications include severe sepsis and septic shock, and these diagnostic and therapeutic approaches are used in hospitals, pathology laboratories, and reference laboratories.

The sepsis market includes revenues earned by entities by providing services such as blood culture testing, molecular diagnostics, biomarker testing, intravenous (IV) fluid management, organ support services, and tele-ICU services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.